Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

Cytarabine, aclarubicin and G-CSF as salvage treatment for hard to treat T cell acute lymphoblastic leukemia

Cytarabine, aclarubicin and G-CSF as salvage treatment for hard to treat T cell acute lymphoblastic leukemia

Posted by on Jun 23, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate cytarabine (Cytosar-U), aclarubicin (Aclacin) and G-CSF (Neupogen) as a salvage treatment for adult patients with relapsed or refractory T cell acute lymphoblastic leukemia.   This study concluded that this treatment combination is safe and effective as a salvage treatment...

Read More

Can immunotherapy increase the effectiveness of following treatments for patients with relapsed or unresponsive non-Hodgkin lymphoma?

Can immunotherapy increase the effectiveness of following treatments for patients with relapsed or unresponsive non-Hodgkin lymphoma?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined if pre-treatment with immunotherapy could improve the effectiveness of following treatment for patients with hard-to-treat non-Hodgkin lymphoma (NHL). The results indicated that immunotherapies increased the effectiveness of other treatments such as chemotherapy for some patients. Some background While...

Read More

Zanubrutinib treatment for relapsed or unresponsive small lymphocytic lymphoma

Zanubrutinib treatment for relapsed or unresponsive small lymphocytic lymphoma

Posted by on May 31, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of zanubrutinib in patients with relapsed/unresponsive chronic lymphocytic leukemia and small lymphocytic lymphoma. This study concluded that zanubrutinib was well tolerated and with promising effectiveness in these patients.    Some background Bruton tyrosine...

Read More

How safe and effective is targeted therapy abemaciclib for patients with relapsed or refractory mantle cell lymphoma?

How safe and effective is targeted therapy abemaciclib for patients with relapsed or refractory mantle cell lymphoma?

Posted by on May 24, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the safety and effectiveness of targeted therapy abemaciclib (Verzenio) for patients with relapsed or refractory mantle cell lymphoma (MCL). The results showed that abemaciclib had promising effectiveness and was relatively safe in these patients. Some background MCL is an aggressive type of lymphoma. During...

Read More

The benefits of repeated cytoreductive surgery and hyperthermic peritoneal chemotherapy in advanced colorectal cancer

The benefits of repeated cytoreductive surgery and hyperthermic peritoneal chemotherapy in advanced colorectal cancer

Posted by on May 21, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the benefits of repeated cytoreductive surgery (CRS) and hyperthermic peritoneal chemotherapy (HIPEC) in patients with advanced colorectal cancer. Researchers suggested that repeated treatment improves the survival of patients with advanced colorectal cancer, without an increase in side effects. Some background...

Read More

Long-term outcomes for CAR-T cells treatment for relapsed or unresponsive chronic lymphocytic leukemia

Long-term outcomes for CAR-T cells treatment for relapsed or unresponsive chronic lymphocytic leukemia

Posted by on May 16, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes of anti-CD19 chimeric antigen receptor T cells in patients with relapsed or refractory (unresponsive) chronic lymphocytic leukemia.  This study concluded that high-dose treatment may be more effective in these patients in the long term.   Some background Chimeric antigen...

Read More

Which low-intensity chemotherapy is most effective for patients with classical Hodgkin lymphoma receiving stem cell transplantation?

Posted by on May 10, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness of three low-intensity chemotherapy combinations to treat patients with classical Hodgkin lymphoma (HL) following stem cell transplantation (SCT). There were no significant differences between the three chemotherapy types in terms of patients’ survival and relapse. Some background...

Read More

Tucatinib in combination with trastuzumab and capecitabine for HER2 positive metastatic breast cancer

Posted by on May 6, 2020 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of tucatinib in combination with trastuzumab and capecitabine in patients with HER2 positive metastatic breast cancer who have had disease progression with other treatments.   This study concluded that this treatment combination was safe and...

Read More

Have the outcomes of stem cell transplants for young patients with relapsed or refractory Hodgkin lymphoma improved over time?

Posted by on Apr 25, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if the outcomes of stem cell transplants (SCT) have improved for young patients with relapsed or refractory Hodgkin lymphoma (HL) over time. The results showed that SCT has improved the survival rate and reduced the relapse rate of HL in young patients in recent years. Some background While initial treatment is...

Read More